Supporting this, several clinical studies in MASLD patients have demonstrated concordance between alterations in CYP enzyme abundance and function (Li et al., 2017; Woolsey et al., 2015; Kawaguchi-Suzuki et al., 2017; Manitpisitkul et al., 2014). The gene discussed is PPIG; the disease is metabolic dysfunction-associated steatotic liver disease.